FluoroPharma Medical, Inc. (FPMI) Takes Aim at the Heart
FluoroPharma Medical, based in Boston, is a developer of imaging agents for use with positron emission tomography (PET). PET is a nuclear medicine imaging technology able to make visible very subtle events occurring deep within the body, uncovering otherwise hidden disease processes prior to the manifestation of more easily identifiable pathologies. PET offers physicians and researchers insights into body dynamics that no other imaging options can, but it won’t work without tracer chemicals that can be linked to and highlight the reactions being investigated, and many current tracers are simply inadequate for what is needed. FluoroPharma, founded by Dr. David…